Investments & business development

Partnering to bring new treatments to patients faster and more efficiently

Contact us

TrialSpark uses balance sheet capital to acquire or license assets to develop, leveraging its unique in-house development engine to run clinical trials significantly faster and more efficiently than the rest of the industry.

  • Licensing and Acquisition

    • Develop as a TrialSpark asset
    • Create a standalone NewCo with joint ownership
    • Alternative structures that include syndication with other investors
  • Investments

    • Equity investments in private and public companies

Learn more

Download an informational deck about our team and partnership offerings.

300+ clinical trials supported

20+ development partners

20+ therapeutic indications

Investments & Business Development Team

Head of Investments

Jorge Ramirez

Jorge Ramirez is the Head of Investments & VP Business Development at TrialSpark. Previously, Jorge was with H.I.G. Capital where he was responsible for development stage and growth investments in the biotechnology, medical device and diagnostics industries. During his six years with H.I.G., Jorge represented the firm in several successful investments. Prior to H.I.G., Jorge was with ProQuest Investments, a healthcare dedicated venture capital firm, and Monitor Company, a strategy consulting firm. He currently serves on the advisory board of the NJ Bioscience Center, a life sciences incubator funded by the NJ Economic Development Authority. Jorge earned degrees in neuroscience and Spanish literature from Amherst College and an M.B.A. from Harvard Business School.

Opal Joshi is a Director of Business Development & Investments at TrialSpark. Prior to TrialSpark, she held Business Development and Investments roles at Flatiron Health and Roivant Sciences. She has experience in strategic partnerships, transactions, in-licensing, acquisitions, and company formation for late-stage and commercial therapeutics. Opal began her investing career at Palladium Equity Partners, and was formerly a consultant at Deloitte Consulting. Opal earned dual-undergraduate degrees from The Ohio State University, and her MBA from the Wharton School of the University of Pennsylvania.

Lamia Mamoon is a Director of Business Development & Investments at TrialSpark where she focuses on strategic partnerships with the biotech sector. Before joining TrialSpark, she was the Head of Business Operations at Floragraph, an early stage microbiome genomic analysis startup. Previously, Lamia was the Head of Business Development at OpenBiome, a microbiome CRO and public stool bank. She also has corporate development experience in the healthcare, education and energy spaces. Lamia earned a BS in Business Administration and Energy and Resources from the University of California, Berkeley. She also holds an MBA from MIT Sloan. She is currently pursuing a masters in Biology and Genomics from Tufts University.

Edward Marks is a Business Development Manager at TrialSpark. Previously, he worked in sell side equity research at Ladenburg Thalmann and H.C. Wainwright covering rare pediatric neurology, neuropsych, and specialty pharmaceuticals. Prior to his equity research roles, Edward worked at Deallus Consulting advising large-cap pharmaceutical clients on competitive strategy and product-market fit with a focus in immune-oncology and neurology. Edward earned his bachelors in Microbial Biotechnology from Rutgers University, and his Masters in Biotechnology and PhD in Molecular Medicine from the University of Delaware.

Ben Liu is the co-founder and CEO of TrialSpark. He received his DPhil at Oxford as a Rhodes Scholar, leveraging machine-learning, AI, and big-data to develop diagnostics and therapeutics for Parkinson’s and Alzheimer’s disease. During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start TrialSpark. Before TrialSpark, Ben graduated from Yale where he was awarded the college’s highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Mellon Fellow.

Ken Somberg is TrialSpark’s Chief Medical Officer. He oversees the medical and scientific aspects of TrialSpark, including asset evaluation, drug development planning, and medical oversight of study conduct. Before joining TrialSpark, Ken was CMO of Nevakar Inc., a company developing ophthalmological and sterile-injectable drugs. Previously, Ken was CMO of Covance for 8 years, held senior positions at Novartis for 12 years, and was the Associate Medical Director of the Liver Transplantation Program at the University of California, San Francisco for 5 years.

Select Advisors

  • Jeff Wilkins, MD

    • Former CMO, Cerecor, Zyla, Lycera, Ceptaris
  • Paul Sekhri

    • Former EVP, Sanofi
    • Former CBO, Teva Pharma
  • Ricardo Dolmetsch, PhD

    • President R&D, uniQure
    • Former NIBR Global Head, Neuroscience
  • Steve Holtzman, PhD

    • Former EVP, Biogen
    • Founder, Infinity Pharma
  • Wendy Johnson

    • Operating Partner, Accelerator Life Sciences
    • CDO, Reneo Pharma
    • BOD, MorphoSys AG
    • BOD, Exagen

Select Investments

spacer-500px-wide
Sponsor Logo - Teres Bio
Sponsor Logo - Tempero Bio
Sponsor Logo - Anteris Bio

Select Partners

spacer-500px-wide
Sponsor Logo - Aditum Bio
Sponsor Logo - Pfizer
Sponsor Logo - Novartis
Sanofi

Let's partner to bring new treatments to patients faster and more efficiently.